婦科治療藥物市場分析及到2017年為止的預測:高未滿足需求促進更年期障礙及骨質疏鬆症市場上Prolia及Odanocantib等新藥的引進 是由出版商GBI Research在2012年01月所出版的。
這份英文市場調查報告書包含Pages: 114 價格從美金3500起跳。
2010年，全球婦女疾病治療藥市場預計為145億美金的規模，2002∼2010年預測以CAGR3.5%成長。該市場到2017年為止更將以CAGR7.9%擴大，而達到246億美金的規模。
本報告提供婦科疾病市場趨勢與收益預測，更年期障礙，停經後骨質疏鬆症，子宮內膜異位症，尿失禁的各領域銷售額，各地區趨勢，開發平台趨勢，競爭情形等彙整資料，為您概述為以下內容。
第1章 目錄
第2章 婦科疾病治療藥物市場(∼2017年):簡介
第3章 婦科疾病治療藥物市場(∼2017年):市場概要
- 簡介
- 收益預測
- 治療的利用模式
- 推動市場的要素·阻礙要素
第4章 婦科疾病治療藥物市場(∼2017年):各地區情況
第5章 婦科疾病治療藥物市場(∼2017年):治療情況
- 更年期障礙
- 簡介
- 銷售額
- 學名藥的市場佔有率
- 年度治療費用
- 治療的利用形態
- 推動市場的要素·阻礙要素
- 停經後骨質疏鬆症
- 子宮內膜異位症
- 尿失禁
第6章 婦科疾病治療藥物市場(∼2017年):開發平台分析
第7章 婦科疾病治療藥物市場(∼2017年):競爭情形
- 市場佔有率分析:婦科疾病市場
- 主要的市售品:婦科疾病市場
- 競爭簡介
第8章 婦科疾病治療藥物市場(∼2017年):收購與合併情況
第9章 婦科疾病治療藥物市場(∼2017年):附錄
圖表
Abstract
Summary
GBI Research finds that the women's health therapeutics market will grow rapidly, largely due to the introduction of new therapies and the increased awareness among patients and physicians in two of the largest segments within WH disorders, the menopause and osteoporosis. Novel non-hormonal therapeutics will become more popular during the forecast period. Though many of the major selling drugs in the osteoporosis market are set to lose patent protection in 2012, the launch of effective therapies such as Prolia (recently launched in 2010) will drive the market revenues. The overall women's health therapeutics market is driven by postmenopausal osteoporosis and menopause. The endometriosis market is heavily genericized and lacks an effective and safe option for the treatment of endometriosis.
In 2010, the women's health therapeutics market was estimated to be worth $14,530m. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of 7.9% between 2010 and 2017 to record a sales value of $24,671m in 2017.
The market has considerable unmet need, as the majority of the diseases in the market are served by hormonal therapeutics. Hormones have been shown to be associated with significant safety issues such as risks of breast cancer and cardiovascular disease. Hence, the use of hormones has declined and women are worried about resuming hormonal therapy for the treatment of the menopause/osteoporosis. There is an opportunity for pharmaceutical companies to develop drugs with greater safety profiles and more competitive prices.
The women's health therapeutics market R&D pipeline is moderately strong, with the majority of first-in-class drugs in late stages of development. These drugs are expected to drive market revenues and it is expected that, if they are approved and are shown to have better safety profiles, patients will comply with novel therapies. In particular, non-hormones are set to take over the conventional hormone therapeutics market.
Scope
- Annualized market data for the women's health disorders market from 2002 to 2010, forecast to 2017.
- Analysis of the leading therapeutic segments, including endometriosis, postmenopausal osteoporosis, menopause and urinary incontinence
- Analysis of the women's health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan
- Market characterization of the women's health therapeutics market, including market size, annual cost of therapy and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, Inc., Eli Lilly and Company, F. Hoffman-La Roche Ltd., Merck and Warner Chilcott Plc.
- Key M&A activities and licensing agreements that took place in 2010 in the women's health therapeutics market
Reasons to buy
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Executive Summary
GBI Research, a leading business intelligence provider, has released its latest research “Women's Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Markets”. The report provides in-depth analysis of the drivers and barriers that affect the Women's Health market and analyzes the markets for women's health disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, revenues, annual cost of therapy and treatment flow algorithm are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. The report also includes insights into the respiratory disorders R&D product pipeline.
It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
The Global Women's Health Therapeutics Market is Forecast to Grow Rapidly from 2010 to 2017
In 2010, the global women's health therapeutics market was estimated to be worth $14,530m, after a Compound Annual Growth Rate (CAGR) of 3.5% between 2002 and 2010. By 2017 the market is estimated to reach $24,671m, indicating a CAGR of 7.9% between 2010 and 2017. Owing to several factors such as the publication of the Women's Health Initiative (WHI) study results, and a lack of effective therapeutics, the women's health therapeutics market grew only moderately between 2002 and 2010. However, the launch of novel therapeutics in the near future is expected to satisfy the unmet need in the market. This will have a pronounced effect on positive growth in the menopause therapeutics market.
The current women's health therapeutics pipeline is promising, with a strong line-up of first-in-class molecules in late stages of clinical development such as Pristiq (desvenlafaxine), Aprela (bazedoxifene/conjugated estrogens), Menerba (MF101) and Elagolix (NBI-56418). In addition, the recent launch of potential blockbuster drugs such as Prolia (denosumab) for the treatment of postmenopausal osteoporosis will offset the patent expirations of several major drugs, including Fosamax (alendronate sodium), Boniva (ibandronate sodium) and Actonel (risedronate sodium). The women's health therapeutics market is an attractive market with huge opportunities for novel entrants with high safety and efficacy profiles.
Novel Therapies are Poised to Dominate the Women's Health Disorder Therapeutics Market
The women's health therapeutics market is backed by a strong pipeline which is expected to drive the growth of this market. Major players such as Pfizer, Inc. and Merck & Co., Inc. have attractive pipelines with many first-in-class molecules for the treatment of the menopause, osteoporosis and endometriosis. If approved, a trend shift in the treatment pattern will be seen, particularly in the menopause and osteoporosis markets.
Amgen Inc recently launched Prolia, a first-in-class drug for the treatment of postmenopausal osteoporosis. Merck's Odanacatib (MK-0822), a cathepsin K inhibitor, has also shown promising results in postmenopausal osteoporosis treatment. The menopause therapeutics market is presently dominated by hormone therapeutics with highly questionable safety profiles. If approved for treatment and shown to be safer, non-hormones for the treatment of menopause will strongly compete with the currently marketed drugs and will significantly alter the market dynamics, with the potential to drive the menopause market sales up to $7,567m by 2017.
Deals Worth Less than $ 1,000m Accounted for 85% of Strategic Consolidations
Strategic consolidations help a company to enter a new market or consolidate its position in the market. The majority (85%) of the merger and acquisition (M&A) deals in the women's health therapeutics market were worth less than $1,000m. Abbott will gain full control of two drugs Tricor (fenofibrate) and Trilipix (fenofibric acid), for treating cholesterol and triglycerides. Table of Contents
1. Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Women's Health Therapeutics Market to 2017 - Introduction
- 2.1 GBI Research Report Guidance
3. Women's Health Therapeutics Market to 2017 - Market Overview
- 3.1 Introduction
- 3.2 Revenue Forecasts for Women's Health Therapeutics Market
- 3.2.1 Revenues
- 3.2.2 Annual Cost of Therapy
- 3.2.3 Generic Share
- 3.3 Treatment Usage Patterns
- 3.4 Drivers and Barriers for Women's Health Therapeutics Market
- 3.4.1 Drivers for Women's Health Therapeutics Market
- 3.4.2 Barriers for Women's Health Therapeutics Market
4. Women's Health Therapeutics Market to 2017 - Geographical Landscape
- 4.1 The US
- 4.1.1 Revenue
- 4.1.2 Annual Cost of Therapy
- 4.1.3 Treatment Usage Pattern
- 4.2 Top Five Countries of Europe
- 4.2.1 Revenue
- 4.2.2 Annual Cost of Therapy
- 4.2.3 Treatment Usage Pattern
- 4.3 Japan
- 4.3.1 Revenue
- 4.3.2 Annual Cost of Therapy
- 4.3.3 Treatment Usage Pattern
5. Women's Health Therapeutics Market to 2017 - Therapeutic Landscape
- 5.1 Menopause
- 5.1.1 Introduction
- 5.1.2 Revenues
- 5.1.3 Generic Share
- 5.1.4 Annual Cost of Therapy
- 5.1.5 Treatment Usage Patterns
- 5.1.6 Drivers and Barriers for Menopause
- 5.2 Post Menopausal Osteoporosis
- 5.2.1 Introduction
- 5.2.2 Revenues
- 5.2.3 Generic Share
- 5.2.4 Annual Cost of Therapy
- 5.2.5 Treatment Usage Patterns
- 5.2.6 Treatment Flow Algorithm
- 5.2.7 Drivers and Barriers for Post Menopausal Osteoporosis
- 5.3 Endometriosis
- 5.3.1 Introduction
- 5.3.2 Revenues
- 5.3.3 Generic Share
- 5.3.4 Annual Cost of Therapy
- 5.3.5 Treatment Usage Patterns
- 5.3.6 Treatment Flow Algorithm
- 5.3.7 Drivers and Barriers for Endometriosis
- 5.4 Urinary Incontinence
- 5.4.1 Introduction
- 5.4.2 Revenues
- 5.4.3 Generic Share
- 5.4.4 Annual Cost of Therapy
- 5.4.5 Treatment Usage Patterns
- 5.4.6 Treatment Flow Algorithm
- 5.4.7 Drivers and Barriers for Urinary Incontinence
6. Women's Health Therapeutics Market to 2017 - Pipeline Analysis
- 6.1 Introduction
- 6.1.1 Research and Development Pipeline - Menopause
- 6.1.2 Research and Development Pipeline - Postmenopausal Osteoporosis
- 6.1.3 Research and Development Pipeline - Endometriosis
- 6.1.4 Research and Development Pipeline - Urinary Incontinence
- 6.2 Profiles of Promising Drugs in the Women's Health Therapeutics Market
- 6.2.1 Aprela (Bazedoxifene/Conjugated Estrogen)
- 6.2.2 Pristiq (Desvenlaxafine, DVS-233)
- 6.2.3 Visanne
- 6.2.4 Elagolix (NBI-56418)
- 6.2.5 Odanacatib (MK-0822)
- 6.2.6 Viviant (Bazedoxifene)
- 6.2.7 YM178
- 6.2.8 GRC 6211
7. Women's Health Therapeutics Market to 2017- Competitive Landscape
- 7.1 Market Share Analysis - Women's Health Therapeutics Market
- 7.2 Major Marketed Products: Women's Health Therapeutics Market
- 7.2.1 Detrol (tolterodine tartrate)
- 7.2.2 Premarin
- 7.2.3 Evista (raloxifene hydrochloride)
- 7.2.4 Actonel (Risedronate sodium)
- 7.3 Competitive Profiling
- 7.3.1 Pfizer
- 7.3.2 Eli-Lilly
- 7.3.3 Merck
- 7.3.4 Roche
- 7.3.5 Warner Chilcott
8. Women's Health Therapeutics Market to 2017 - M&A Landscape
- 8.1 M&A Landscape
- 8.1.1 M&A Deals by Year
- 8.1.2 M&A Deals by Deal Type
- 8.1.3 M&A Deals by Geography
- 8.1.4 M&A Deals by Value
- 8.1.5 Top Five M&A Deals by Value
- 8.2 R&D Licensing Agreements
- 8.2.1 Deals by Year
- 8.2.2 Deals by Geography
- 8.2.3 Deals by Value ($)
- 8.3 Co-Development Agreements
- 8.3.1 Co-Development Agreements by Year
- 8.3.2 Co-Development Agreements by Geography
- 8.3.3 Co-Development Agreements by Value
9. Women's Health Therapeutics Market to 2017 - Appendix
- 9.1 Market Definitions
- 9.2 Abbreviations
- 9.3 Research Methodology
- 9.3.1 Coverage
- 9.3.2 Secondary Research
- 9.3.3 Primary Research
- 9.3.4 Section Wise Methodology
- 9.3.5 Expert Panel Validation
- 9.4 Contact Us
- 9.5 Disclaimer
- 9.6 Sources
List of Tables
- Table 1: Women's Health Therapeutics Market, Global, Revenue, ($m), 2002 - 2010
- Table 2: Women's Health Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017
- Table 3: Women's Health Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010
- Table 4: Women's Health Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017
- Table 5: Women's Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010
- Table 6: Women's Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017
- Table 7: Women's Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010
- Table 8: Women's Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017
- Table 9: Women's Health Therapeutics Market, The US, Revenue, ($m), 2002 - 2010
- Table 10: Women's Health Therapeutics Market, The US, Revenue Forecasts, ($m), 2010 - 2017
- Table 11: Women's Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2002 - 2010
- Table 12: Women's Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2010 - 2017
- Table 13: Women's Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002 - 2010
- Table 14: Women's Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2010 - 2017
- Table 15: Women's Health Therapeutics Market, Top Five Countries of Europe, Revenue, ($m), 2002 - 2010
- Table 16: Women's Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($m), 2010 - 2017
- Table 17: Women's Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002-2010
- Table 18: Women's Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2010 - 2017
- Table 19: Women's Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002 - 2010
- Table 20: Women's Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2010 - 2017
- Table 21: Women's Health Therapeutics Market, Japan, Revenue, ($m), 2002 - 2010
- Table 22: Women's Health Therapeutics Market, Japan, Revenue Forecasts, ($m), 2010 - 2017
- Table 23: Women's Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002 - 2010
- Table 24: Women's Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2010- 2017
- Table 25: Women's Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002 - 2010
- Table 26: Women's Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2010 - 2017
- Table 27: Menopause Therapeutics Market, Global, Revenue, ($m), 2002 - 2010
- Table 28: Menopause Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017
- Table 29: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010
- Table 30: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2010 -2017
- Table 31: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010
- Table 32: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017
- Table 33: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010
- Table 34: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017
- Table 35: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue, ($m), 2002 - 2010
- Table 36: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017
- Table 37: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010
- Table 38: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017
- Table 39: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010
- Table 40: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017
- Table 41: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010
- Table 42: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017
- Table 43: Endometriosis Therapeutics Market, Global, Revenue, ($m), 2002 - 2010
- Table 44: Endometriosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017
- Table 45: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010
- Table 46: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017
- Table 47: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010
- Table 48: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017
- Table 49: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002 - 2010
- Table 50: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2010 - 2017
- Table 51: Urinary Incontinence Therapeutics Market, Global, Revenue, ($m), 2002 - 2010
- Table 52: Urinary Incontinence Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017
- Table 53: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010
- Table 54: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017
- Table 55: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010
- Table 56: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017
- Table 57: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010
- Table 58: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017
- Table 59: Women's Health Therapeutics Market, Global, Pipeline by Phase, 2011
- Table 60: Women's Health Therapeutics Market, Global, Pipeline by Indication, 2011
- Table 61: Menopause Therapeutics Market, Global, Pipeline, Pre-Clinical Stage Molecules, 2011
- Table 62: Menopause Therapeutics Market, Global, Pipeline, IND Filed Stage Molecules, 2011
- Table 63: Menopause Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011
- Table 64: Menopause Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011
- Table 65: Menopause Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011
- Table 66: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011
- Table 67: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011
- Table 68: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011
- Table 69: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011
- Table 70: Endometriosis Therapeutics Market, Pipeline, Global, Pre-Clinical Stage Molecules, 2011
- Table 71: Endometriosis Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011
- Table 72: Endometriosis Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011
- Table 73: Endometriosis Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011
- Table 74: Urinary Incontinence Therapeutics Market, Global, Pipeline, Pre-Clinical Stage Molecules, 2011
- Table 75: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011
- Table 76: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011
- Table 77: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011
- Table 78: Urinary Incontinence Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011
- Table 79: Women's Health Therapeutics Market, Marketed Drug Revenues, 2010
- Table 80: Women's Health Therapeutics Market, Global, M&A Deals by Type, 2004-2011
- Table 81: Women's Health Therapeutics Market, Global, M&A Deals by Geography, 2004-2011
- Table 82: Women's Health Therapeutics Market, Global, M&A Deals by Value, 2004-2011
- Table 83: Women's Health Therapeutics Market, Global, Top Five M&A Deals by Value, ($m), 2005-2010
- Table 84: Women's Health Therapeutics Market, Global, Licensing Agreements by Geography, 2004-2011
- Table 85: Women's Health Therapeutics Market, Global, Licensing Agreements by Value, ($m), 2004-2011
- Table 86: Women's Health Therapeutics Market, Global, Co-Development Agreements by Geography, 2004-2011
- Table 87: Women's Health Therapeutics Market, Global, Co-Development Agreements by Value, ($m), 2004-2011
List of Figures
- Figure 1: Women's Health Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017
- Figure 2: Women's Health Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017
- Figure 3: Women's Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017
- Figure 4: Women's Health Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017
- Figure 5: Women's Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017
- Figure 6: Women's Health Therapeutics Market, Global, Drivers and Barriers, 2010
- Figure 7: Women's Health Therapeutics Market, The US, Revenue Forecasts, ($m), 2002 - 2017
- Figure 8: Women's Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2002 - 2017
- Figure 9: Women's Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002 - 2017
- Figure 10: Women's Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($m), 2002 - 2017
- Figure 11: Women's Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002 - 2017
- Figure 12: Women's Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002 - 2017
- Figure 13: Women's Health Therapeutics Market, Japan, Revenue Forecasts, ($m), 2002 - 2017
- Figure 14: Women's Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002 - 2017
- Figure 15: Women's Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002 - 2017
- Figure 16: Menopause Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017
- Figure 17: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017
- Figure 18: Menopause Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017
- Figure 19: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017
- Figure 20: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017
- Figure 21: Menopause Therapeutics Market, Global, Drivers and Barriers, 2010
- Figure 22: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017
- Figure 23: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017
- Figure 24: Post Menopausal Osteoporosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017
- Figure 25: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017
- Figure 26: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017
- Figure 27: Post Menopausal Osteoporosis Therapeutics Market, Treatment Flow Algorithm, 2010
- Figure 28: Post Menopausal Osteoporosis Therapeutics Market, Global, Drivers and Barriers, 2010
- Figure 29: Endometriosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017
- Figure 30: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017
- Figure 31: Endometriosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017
- Figure 32: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017
- Figure 33: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, ('000), 2002 - 2017
- Figure 34: Endometriosis Therapeutics Market, Treatment Flow Algorithm, 2010
- Figure 35: Endometriosis Therapeutics Market, Global, Drivers and Barriers, 2010
- Figure 36: Urinary Incontinence Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017
- Figure 37: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017
- Figure 38: Urinary Incontinence Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017
- Figure 39: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017
- Figure 40: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017
- Figure 41: Women's health Therapeutics to 2017, UI Treatment Algorithm Part-1
- Figure 42: Women's Health Therapeutics to 2017, UI Treatment Algorithm, Part-2
- Figure 43: Urinary Incontinence Therapeutics Market, Global, Drivers and Barriers, 2010
- Figure 44: Women's Health Therapeutics Market, Global, Pipeline by Phase, (%), 2011
- Figure 45: Women's Health Therapeutics Market, Global, Pipeline by Indication (%), 2011
- Figure 46: Women's Health Therapeutics Market, Market Share Analysis, (%), 2010
- Figure 47: Women's Health Therapeutics Market, Pfizer SWOT Analysis, 2011
- Figure 48: Women's Health Therapeutics Market, Eli-Lilly SWOT Analysis, 2011
- Figure 49: Women's Health Therapeutics Market, Merck SWOT Analysis, 2011
- Figure 50: Women's Health Therapeutics Market, Roche SWOT Analysis, 2011
- Figure 51: Women's Health Therapeutics Market, Warner Chilcott SWOT Analysis, 2011
- Figure 52: Women's Health Therapeutics Market, Global, M&A Deals by Year, 2004-2011
- Figure 53: Women's Health Therapeutics Market, Global, M&A Deals by Type, (%), 2004-2011
- Figure 54: Women's Health Therapeutics Market, Global, M&A Deals by Geography, (%), 2004-2011
- Figure 55: Women's Health Therapeutics Market, Global, M&A Deals by Value, (%), 2004-2011
- Figure 56: Women's Health Therapeutics Market, Global, Licensing Agreements by Year, 2004-2011
- Figure 57: Women's Health Therapeutics Market, Global, Licensing Agreements by Geography, (%), 2004-2011
- Figure 58: Women's Health Therapeutics Market, Global, Licensing Agreements by Value, (%), 2004-2011
- Figure 59: Women's Health Therapeutics Market, Global, Co-Development Agreements by Year, 2004-2011
- Figure 60: Women's Health Therapeutics Market, Global, Co-Development Agreements by Geography, (%), 2004-2011
- Figure 61: Women's Health Therapeutics Market, Global, Co-Development Agreements by Value, (%), 2004-2011
- Figure 62: GBI Research Market Forecasting Model
|
